SRI International Names Luther Lau Chief Financial Officer

MENLO PARK, Calif., Dec. 15, 2014 /PRNewswire/ -- SRI International has selected Luther Lau as Chief Financial Officer (CFO). Lau has served as SRI's acting CFO since March 2014. In his new position, Lau will continue leading SRI's financial, internal audit, corporate security, environmental health and safety, facilities and logistics teams.

SRI International CFO Luther Lau
"As acting CFO, Luther made substantial contributions in ensuring the financial strength of the enterprise and in supporting the long term business strategy," said Bill Jeffrey, Ph.D., president and CEO, SRI International. "I am pleased to welcome Luther as a full member of SRI's executive team and look forward to his leadership of critical business functions."

Lau joined SRI in 2011 and has more than 25 years of financial management experience. Prior to SRI, Lau held executive and management roles at CNA Corporation, SAIC, Northrop Grumman, and Atlantic Richfield Company (ARCO).

Lau holds an MBA in finance from the Marshall School, University of Southern California, and a BS in accounting and organizational management from the Wharton School, University of Pennsylvania.              

About SRI International

SRI international is a leader in research and development whose innovations have created new industries, extraordinary marketplace value and lasting benefits to society. SRI provides government and business with pioneering R&D and solutions in biosciences, chemistry and materials, computing, education, engineering, security and defense, sensing and devices, and more. SRI brings its innovations to the marketplace through technology licensing, spin-off ventures and new products.

Photo -

To view the original version on PR Newswire, visit:

SOURCE SRI International

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.